RecruitingNot ApplicableNCT05265520

His-Bundle Corrective Pacing in Heart Failure


Sponsor

University of Rochester

Enrollment

120 participants

Start Date

Dec 2, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The investigators aim to prospectively evaluate the efficacy and mechanism of benefit of His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle branch block (RBBB).


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Age 18 years or older (no upper age limit)
  • Optimal medical therapy for heart failure by current guidelines
  • Class IIa or IIb guideline-based indication for CRT-D implant in RBBB patients, including one of the following:
  • New York Heart Association (NYHA) class II HF symptoms, LVEF ≤ 30% and QRS≥ 150 ms (IIb); OR
  • NYHA class III-IV a HF, LVEF ≤ 35%, and QRS duration ≥ 150 ms (IIa); OR
  • NYHA class III-IV a HF, LVEF ≤ 35%, and QRS duration 120-149 ms (IIb)

Exclusion Criteria6

  • Unable to obtain most recent imaging data from echocardiogram within 1 year prior to date of randomization
  • Left bundle branch block (LBBB) or intraventricular conduction delay (IVCD) ECG morphology
  • Unable or unwilling to follow study protocol
  • Less than 12 months life expectancy at consent
  • Pregnancy or planned pregnancy during duration of the study
  • On heart transplant list or likely to undergo heart transplant

Interventions

PROCEDUREHis-CRT implantation

The pathophysiological process is utilized in His-Bundle corrective pacing, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular endocardial lead.

PROCEDUREBIV-CRT implantation

Biventricular cardiac resynchronization therapy has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.


Locations(14)

University of Arizona

Phoenix, Arizona, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

University of South Florida

Tampa, Florida, United States

Northwestern Memorial Hospital

Chicago, Illinois, United States

Rush University Medical Center

Chicago, Illinois, United States

University of Chicago

Chicago, Illinois, United States

Valley Health System

Ridgewood, New Jersey, United States

Weill Cornell Medical College

New York, New York, United States

Mount Sinai Hospital

New York, New York, United States

Mission Health

Asheville, North Carolina, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Geisinger Wyoming Valley

Wilkes-Barre, Pennsylvania, United States

University of Vermont

Burlington, Vermont, United States

Virginia Commonwealth University

Richmond, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05265520


Related Trials